We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
-6.45%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$20.6M
Cap. Flow
+$957K
Cap. Flow %
0.85%
Top 10 Hldgs %
39.2%
Holding
84
New
25
Increased
14
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$4.87M
2
GERN icon
Geron
GERN
+$4.03M
3
VRDN icon
Viridian Therapeutics
VRDN
+$3.7M
4
DYN icon
Dyne Therapeutics
DYN
+$3.7M
5
RGNX icon
Regenxbio
RGNX
+$3.01M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.58M
2
RLAY icon
Relay Therapeutics
RLAY
+$4.46M
3
APLS
Apellis Pharmaceuticals
APLS
+$3.81M
4
BMY icon
Bristol-Myers Squibb
BMY
+$3.69M
5
BSX icon
Boston Scientific
BSX
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
51
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$129K 0.12%
+37,500
New +$1.73M
RYTM icon
52
PUT
Rhythm Pharmaceuticals
RYTM
$6.84B
$70K 0.06%
+40,000
New +$2.22M
APRE icon
53
Aprea Therapeutics
APRE
$7.49M
$59.1K 0.05%
28,972
-98,988
-77% -$310K
GOSS icon
54
CALL
Gossamer Bio
GOSS
$83.1M
$47.5K 0.04%
+100,000
New +$116K
NKTR icon
55
CALL
Nektar Therapeutics
NKTR
$2.38B
$22.5K 0.02%
+5,000
New +$65.3K
ROIV icon
56
PUT
Roivant Sciences
ROIV
$23.9B
$15.1K 0.01%
+75,300
New +$814K
VERU icon
57
CALL
Veru
VERU
$36.1M
$900 ﹤0.01%
+6,000
New +$37.2K
SLNO
58
PUT
DELISTED
Soleno Therapeutics
SLNO
$275 ﹤0.01%
+11,000
New +$536K
ABUS icon
59
Arbutus Biopharma
ABUS
$865M
– –
-28,300
Closed -$92.5K
ACRS icon
60
Aclaris Therapeutics
ACRS
$728M
– –
-389,333
Closed -$966K
ANNX icon
61
Annexon
ANNX
$852M
– –
-144,830
Closed -$743K
APLS
62
DELISTED
Apellis Pharmaceuticals
APLS
– –
-119,467
Closed -$3.81M
BMY icon
63
Bristol-Myers Squibb
BMY
$132B
– –
-65,200
Closed -$3.69M
BPMC
64
DELISTED
Blueprint Medicines
BPMC
– –
-31,800
Closed -$2.77M
BSX icon
65
Boston Scientific
BSX
$71.1B
– –
-40,500
Closed -$3.62M
GILD icon
66
Gilead Sciences
GILD
$161B
– –
-29,700
Closed -$2.74M
HUM icon
67
Humana
HUM
$44.2B
– –
-18,066
Closed -$4.58M
JANX icon
68
Janux Therapeutics
JANX
$926M
– –
-40,123
Closed -$2.15M
LEGN icon
69
Legend Biotech
LEGN
$3.69B
– –
-37,600
Closed -$1.22M
CYPH
70
Cypherpunk Technologies Inc
CYPH
$68.4M
– –
-102,631
Closed -$295K
MDGL icon
71
Madrigal Pharmaceuticals
MDGL
$11B
– –
-987
Closed -$305K
MRSN
72
DELISTED
Mersana Therapeutics
MRSN
– –
-6,917
Closed -$250K
NMRA icon
73
CALL
Neumora Therapeutics
NMRA
$306M
– –
-600
Closed -$207K
NUVL
74
DELISTED
Nuvalent
NUVL
– –
-40,580
Closed -$3.19M
PLRX icon
75
Pliant Therapeutics
PLRX
$65M
– –
-103,504
Closed -$1.36M
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Exome Asset Management held 84 positions worth $112M, down 15% from $133M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Exome Asset Management's Q1 2025 filing shows 25 new, 14 increased, 14 reduced and 25 closed positions. Its largest new stake was Cogent Biosciences: 621,678 shares worth $3.72M. The largest sale was Humana, an estimated $4.58M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

  • Exome Asset Management's largest Q1 2025 buy was Cogent Biosciences: 621,678 shares worth $3.72M.
  • Exome Asset Management added most to Geron in Q1 2025, an estimated $4.03M increase.
  • Exome Asset Management's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $2.97M.
  • Exome Asset Management fully exited Humana in Q1 2025, selling an estimated $4.58M.
  • Exome Asset Management's ten largest holdings make up 39% of its $112M portfolio in Q1 2025.
  • Exome Asset Management opened 25 new positions and closed 25 in Q1 2025.
  • Exome Asset Management's portfolio value fell 15% quarter-over-quarter to $112M.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.